DXCM vs SENS

Dexcom maintains its strong position as a Continuous Glucose Monitoring (CGM) market leader, driven by successful G7 global rollout and promising initial penetration of Stelo into the Type 2 non-insulin market. The company exhibits solid financial health, consistent operational execution (Q4 2025 earnings beat), and positive analyst sentiment with recent upgrades. The absence of previous concerns ...

Senseonics (SENS) continues to present an extremely high-risk, high-reward profile with the path to 10x potential remaining significantly challenging. While the Eversense long-term implantable CGM offers a unique proposition in the vast diabetes market, previous commercialization struggles and persistent cash burn are still critical concerns. The market cap has slightly adjusted from the previous ...